|Molecule Type||Antigen Expression||Molecular Weight|
Min / Max
|Lineage Restricted Molecule|
|CD175s is expressed on endothelial and epithelial cells and erythroblasts. It is expressed by breast, ovary, colorectal, gastrointestinal, bladder, larynx and lung carinoma cells.|
|MOLECULAR FAMILY NAME: Belongs to the carbohydrate chain.|
CD175s is the sialylated epitope on O-linked monosaccharide GalNAcα1-O-R, expressed on glycosphingolipid or glycoprotein.
POST-TRANSCRIPTIONAL MODIFICATION: No information.
POST-TRANSLATIONAL MODIFICATION: No information.
| LIGANDS AND MOLECULES ASSOCIATED WITH CD175s: No information.|
|CD175s has shown binding to CD22, Siglec-3-5 and 6. |
BIOCHEMICAL ACTIVITY: No information.
DISEASE RELEVANCE AND FUNCTION OF CD175s IN INTACT ANIMAL
CD175 has been implicated in the induction of metastasis and invasiveness of tumors. It is overexpressed in several carcinomas and is associated with poor prognosis. CD175s is a vaccine candidate for colorectal and non-small cell lung cancer.CD175s conjugated to keyhole limpet hemocyanin (Theratope) is being trialed as a vaccine for colorectal and non-small cell lung cancer. A large scale phase III clinical trial of Theratope in breast cancer patients was completed in 2003 and it is currently neing assessed in patients with metastatic breast cancer. Transfection of CD175s-ve breast cancer cell lines with ST6GalNAc1 cDNA results in expression of CD175s and decreased adhesion and increased migration of cells.
|MOLECULAR INTERACTIONS -|
PROTEINS AND DNA ELEMENTS WHICH REGULATE TRANSCRIPTION OF CD175s: No information.
SUBSTRATES: No information.
ENZYMES WHICH MODIFY CD175s: No information.
Database accession numbers
Revised June 25, 2008